Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annovis Bio, Inc.

3.21
+0.16005.25%
Post-market: 3.300.0850+2.65%19:59 EDT
Volume:633.88K
Turnover:2.05M
Market Cap:62.55M
PE:-1.53
High:3.40
Open:3.09
Low:3.03
Close:3.05
Loading ...

Top Premarket Decliners

MT Newswires Live
·
03 Feb

BUZZ-Annovis Bio slides after $21 mln stock offering

Reuters
·
03 Feb

Annovis Bio Inc - Prices Public Offering of 5.25 Mln Shares at $4.00 Each

THOMSON REUTERS
·
03 Feb

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

GlobeNewswire
·
03 Feb

Annovis Bio, Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
01 Feb

Annovis Bio, Inc. Announces Proposed Public Offering

GlobeNewswire
·
01 Feb

Annovis Bio Receives US Patent for Treating Acute Brain, Nerve Injuries With Buntanetap

MT Newswires Live
·
14 Jan

Annovis Bio granted U.S. patent covering buntanetap

TIPRANKS
·
14 Jan

Annovis Bio Inc: Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

THOMSON REUTERS
·
14 Jan

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

GlobeNewswire
·
14 Jan

Annovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy Rating

TIPRANKS
·
09 Jan

Annovis Bio Says FDA Approved Revised Protocol for Phase 3 Alzheimer's Disease Study

MT Newswires Live
·
08 Jan

BUZZ-Annovis Bio rises as FDA approves late-stage Alzheimer's study protocol

Reuters
·
07 Jan

Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study

TIPRANKS
·
07 Jan

BRIEF-FDA Accepts Final Protocol For Pivotal Phase 3 Alzheimer’S Disease Study, Streamlining Development Pathway

Reuters
·
07 Jan

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

THOMSON REUTERS
·
07 Jan

Annovis Bio Inc - Revised Protocol Includes 6-Month Symptomatic and 12-Month Disease-Modifying Assessment

THOMSON REUTERS
·
07 Jan

Annovis Bio Inc - Integrates Phase 3 Ad Studies Into Single 6/18-Month Trial

THOMSON REUTERS
·
07 Jan

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

GlobeNewswire
·
07 Jan

BUZZ-Annovis Bio falls on planned $50 mln share sale

Reuters
·
11 Dec 2024